NASDAQ:CATB

Catabasis Pharmaceuticals Stock Forecast, Price & News

$2.24
-0.13 (-5.49 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.15
Now: $2.24
$2.35
50-Day Range
$2.37
MA: $2.97
$3.58
52-Week Range
$1.25
Now: $2.24
$8.59
Volume771,738 shs
Average Volume5.37 million shs
Market Capitalization$52.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Catabasis Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971
Employees20
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.87 per share

Profitability

Net Income$-26,290,000.00

Miscellaneous

Market Cap$52.45 million
Next Earnings Date5/11/2021 (Estimated)
OptionableNot Optionable

Headlines

Can't Get My Head Around Catabasis Pharmaceuticals
February 18, 2021 |  seekingalpha.com
Catabasis -64% after halting development of edasalonexent
October 26, 2020 |  seekingalpha.com
Catabasis names Noah Clauser as CFO
September 21, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

357th out of 2,024 stocks

Pharmaceutical Preparations Industry

165th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
$2.24
-0.13 (-5.49 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

Is Catabasis Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Catabasis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CATB, but not buy additional shares or sell existing shares.
View analyst ratings for Catabasis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Catabasis Pharmaceuticals?

Wall Street analysts have given Catabasis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catabasis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Catabasis Pharmaceuticals
.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) posted its quarterly earnings data on Wednesday, March, 10th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.07.
View Catabasis Pharmaceuticals' earnings history
.

How has Catabasis Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Catabasis Pharmaceuticals' stock was trading at $4.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CATB shares have decreased by 49.5% and is now trading at $2.24.
View which stocks have been most impacted by COVID-19
.

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Catabasis Pharmaceuticals shares reverse split on the morning of Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CATB?

3 equities research analysts have issued 1-year price targets for Catabasis Pharmaceuticals' stock. Their forecasts range from $5.00 to $24.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $14.67 in the next year. This suggests a possible upside of 554.8% from the stock's current price.
View analysts' price targets for Catabasis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the following people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 53, Pay $734.54k)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 60, Pay $512.64k)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 64, Pay $594.41k)
  • Mr. Noah Clauser CPA, Chief Financial Officer (Age 48)
  • Mr. Benjamin S. Harshbarger J.D., Sr. VP & Gen. Counsel (Age 52)
  • Ms. Andrea L. Matthews, Sr. VP of Corp. Affairs
  • Mr. Andrew A. Komjathy, Chief Commercial Officer (Age 58)

Who are some of Catabasis Pharmaceuticals' key competitors?

What other stocks do shareholders of Catabasis Pharmaceuticals own?

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $2.24.

How much money does Catabasis Pharmaceuticals make?

Catabasis Pharmaceuticals has a market capitalization of $52.45 million. The biotechnology company earns $-26,290,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

How many employees does Catabasis Pharmaceuticals have?

Catabasis Pharmaceuticals employs 20 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is www.catabasis.com.

Where are Catabasis Pharmaceuticals' headquarters?

Catabasis Pharmaceuticals is headquartered at 100 High StreetFloor 28, Boston MA, 02110.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.